Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 18/3/2019
SIETES contiene 92692 citas

 
 
 1 a 20 de 28 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Wallach JD, Eqilman AC, Dhruva SS, McCarthy ME, Miller JE, Woloshin S, Schwartz LM, Ross JS. Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis. BMJ 2018;361:24 de mayo. [Ref.ID 102886]
2. Cita con resumen
Woloshin S, Schwartz LM, White B, Moore TJ. The fate of FDA postapproval studies. N Engl J Med 2017;377:1114-7. [Ref.ID 102072]
3.Tiene citas relacionadas Cita con resumen
Woloshin S, Schwartz LM. US Food and Drug Administration approval of flibanserin: even the score does not add up. JAMA Intern Med 2016;176:439-42. [Ref.ID 100197]
4.Tiene citas relacionadas Cita con resumen
Woloshin S, Schwartz LM. US Food and Drug Administration approval of flibanserin. Even the score does not add up . JAMA Intern Med 2016;176:439-42. [Ref.ID 100071]
5. Cita con resumen
Kesselheim AS, Campbell EG, Schneeweiss S, Rausch P, Lappin BM, Zhou EH, Seeger JD, Brownstein JS, Woloshin S, Schwartz LM, Toomey T, Dal Pan GJ, Avorn J. Methodological approaches to evaluate the impact of FDA drug safety communications. Drug Saf 2015;38:565-75. [Ref.ID 99239]
6. Cita con resumen
Woloshin S, Schwartz LM. The new weight-loss drugs, Lorcaserin and Phentermine-topiramate. Slim pickings?. JAMA Intern Med 2014;174:615-9. [Ref.ID 97426]
7. Cita con resumen
Morden NE, Schwartz LM, Fisher ES, Woloshin S. Accountable prescribing. N Engl J Med 2013;369:299-302. [Ref.ID 95875]
8.Tiene citas relacionadas Cita con resumen
Sahasrabuddhe VV, Gunja MZ, Graubard BI, Trabert B, Schwartz LM, Park Y, Hollenbeck AR, Freedman ND, McGlynn KA. Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma. Journal of National Cancer Institute 2012;104:1808-14. [Ref.ID 93263]
9. Cita con resumen
Schwartz LM, Woloshin S. How the FDA forgot the evidence: donepezil 23 mg. BMJ 2012;344:40-1. [Ref.ID 92650]
10. Cita con resumen
Schwartz LM, Woloshin S. How the FDA forgot the evidence: the case of donepezil 23 mg. BMJ 2012;344:e1086. [Ref.ID 92531]
11. Cita con resumen
Woloshin S, Schwartz LM. Communicating data about the benefits and harms of treatment. A randomized trial. Ann Intern Med 2011;155:87-96. [Ref.ID 91391]
12.Tiene citas relacionadas
Woloshin S, Schwartz LM. The benefits and harms of mammography screening. Understanding the trade-offs. JAMA 2010;303:164-5. [Ref.ID 87591]
13.Tiene citas relacionadas
Woloshin S, Schwartz LM. Does direct-to-consumer prescription drug advertising do more harm than good? In response. Ann Intern Med 2009;151:824. [Ref.ID 87420]
14.Tiene citas relacionadas
Woloshin S, Schwartz LM. Bringing the FDA's information to market. Arch Intern Med 2009;169:1985-7. [Ref.ID 87124]
15. Cita con resumen
Schwartz LM, Woloshin S. Lost in transmission — FDA drug information that never reaches clinicians. N Engl J Med 2009;361:1717-20. [Ref.ID 86923]
16. Cita con resumen
Woloshin S, Schwartz LM, Casella SL, Kennedy AT, Larson RJ. Press releases by academic medical centers: not so academic?. Ann Intern Med 2009;150:613-8. [Ref.ID 85874]
17. Cita con resumen
Schwartz LM, Woloshin S, Dvorin EL, Welch HG. Ratio measures in leading medical journals: structured review of accessibility of underlying absolute risks. BMJ 2006;333:1248-50. [Ref.ID 78879]
18.
Kallen AJ, Wilson CT, Russell MA, Larson RJ, Davies L, Sirovich BE, Schwartz LM, Woloshin S. Group writing of letters to the editor as the goal of journal club. JAMA 2006;296:1053-4. [Ref.ID 77935]
19.Enlace a cita originalTiene citas relacionadas Cita con resumen
Woloshin S, Schwartz LM. Giving legs to restless legs: a case study of how the media helps make people sick. PLOS Medicine 2006;3:170. [Ref.ID 77892]
20. Cita con resumen
Welch HG, Woloshin S, Schwartz LM. Skin biopsy rates and incidence of melanoma: population based ecological study. BMJ 2005;331:481-4. [Ref.ID 74729]
Seleccionar todas
 
 1 a 20 de 28 siguiente >>